Novo Nordisk Sees Massive Sales Jump, Expects Further Growth in 2024
Novo Nordisk, a leading pharmaceutical company, witnessed a remarkable 31% surge in overall sales in 2023 compared to the previous year. The company anticipates an additional growth rate ranging from 18% to 26% this year. This exceptional growth is fueled by the soaring demand for Novo Nordisk’s highly sought-after drugs for diabetes and weight-loss, namely Ozempic and Wegovy.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
